SCHEMBL723399

SCHEMBL723399

Cc1cccc(-c2cc3nccc(Nc4ccc5[nH]ccc5c4C)c3o2)c1

nearest known ligand 0.40

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PRKCQ Q04759 14/20 0.40
PRKCD Q05655 14/20 0.40
KDR P35968 2/20 0.38
LYN P07948 2/20 0.37
PRKCB P05771 1/20 0.37
LCK P06239 1/20 0.37
PRKCH P24723 1/20 0.37
PRKCE Q02156 1/20 0.37
MAPKAPK2 P49137 2/20 0.36
EGFR P00533 1/20 0.35
PDGFRB P09619 1/20 0.35
MAP4K4 O95819 1/20 0.34
TGFBR1 P36897 1/20 0.34
P2RX7 Q99572 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL723524 0.91 PRKCQ (0.44) PRKCQPRKCDKDRLYNPRKCB
SCHEMBL723489 0.91 PRKCQ (0.37) PRKCQPRKCDLYNPRKCBLCK
SCHEMBL721627 0.89 MAPKAPK2 (0.40) PRKCQPRKCDKDRLYNPRKCB
SCHEMBL10268104 0.89 PRKCQ (0.51) PRKCQPRKCDMAPKAPK2
SCHEMBL725010 0.84 PRKCQ (0.50) PRKCQPRKCDLYNLCKEGFR
SCHEMBL726781 0.84 PRKCQ (0.34) PRKCQPRKCDLYNPRKCBLCK
SCHEMBL10267539 0.83 PRKCQ (0.47) PRKCQPRKCDKDRLYNPRKCB
SCHEMBL722230 0.83 ADRA2A (0.39) PRKCQPRKCDKDRLYNLCK
SCHEMBL721499 0.83 PRKCQ (0.43) PRKCQPRKCDLYNLCKP2RX7
SCHEMBL723572 0.83 CLK4 (0.40) PRKCQPRKCDKDRLYNLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP claimed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP claimed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO claimed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
EP-2609100-B1 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2015-06-24 EP disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-9006440-B2 Furopyridine derivatives MERCK PATENT GMBH (DE) 2015-04-14 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
US-20130225569-A1 FUROPYRIDINE DERIVATIVES MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2013-08-29 US disclosed
EP-2609100-A2 FUROPYRIDINE DERIVATIVES Merck Patent GmbH (DE) 2013-07-03 EP disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed
WO-2012025187-A2 FUROPYRIDINE DERIVATIVES MERCK PATENT GMBH (DE) 2012-03-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130225569-A1 FUROPYRIDINE DERIVATIVES SYK, FCGRT, SSB PRKCQ 662/4885PRKCD 964/4885KDR 263/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.